500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to
help focus thin beams of radiation directly on the tumor, and giving hypofractionated
radiation therapy (higher doses over a shorter period of time), may kill more tumor cells
and have fewer side effects. It is not yet known which radiation therapy regimen is more
effective in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying several different radiation therapy
regimens to compare how well they work in treating patients with stage II prostate cancer.
Active, not recruiting
Ages:18 and older
DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate within the past 6 months - Clinical stage T1-2c - Combined Gleason score 2-6 - Prostate-specific antigen (PSA) < 10 ng/mL within the past 6 months - No PSA measurement for ≥ 10 days after prostate biopsy - No PSA measurement for ≥ 30 days after discontinuation of finasteride (90 days after discontinuation of dutasteride) - No regional lymph node involvement - No distant metastases PATIENT CHARACTERISTICS: - Zubrod performance status 0-1 - No unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months - No transmural myocardial infarction within the past 6 months - No acute bacterial or fungal infection requiring IV antibiotics - No chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study treatment - No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects - No known AIDS - No prior or concurrent lymphomatous/hematogenous malignancy or other invasive malignancy except nonmelanomatous skin cancer or any other cancer for which the patient has been continually disease-free for ≥ 5 years (e.g., carcinoma in situ of the bladder or oral cavity) - No other severe, active comorbidity PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior radical prostatectomy or cryosurgery for prostate cancer - No prior hormonal therapy, including any of the following: - Luteinizing hormone-releasing hormone agonists (e.g., goserelin or leuprolide) - Antiandrogens (e.g., flutamide or bicalutamide) - Estrogens (e.g., diethylstilbestrol [DES]) - Surgical castration (bilateral orchiectomy) - No prior pelvic radiotherapy or prostate brachytherapy - No prior or concurrent cytotoxic chemotherapy for prostate cancer - At least 30 days since prior finasteride - At least 90 days since prior dutasteride - No concurrent neoadjuvant or adjuvant hormonal therapy - Concurrent warfarin or other blood-thinning agents allowed
Sponsor: Radiation Therapy Oncology Group
Phase: Phase 3
Trial ID: NCT00331773
Not Accepting Healthy Volunteers